Activ Surgical, which develops digital surgery systems, announced that it has completed its first artificial intelligence (AI)-enabled case using its ActivSight Intelligent Light (ActivSight), which is designed to provide enhanced visualization and real-time, on-demand surgical insights in the operating room. ActivSight is a module that attaches to today’s laparoscopic and robotic systems and integrates with standard monitors.
Activ Surgical said that on December 22, 2022, Matthew Kalady, chief of the division of colon and rectal surgery at The Ohio State University Wexner Medical Center, performed a laparoscopic left colectomy, which is the surgical removal of the left side of the large bowel most often due to colon cancer, using the colorectal AI mode within ActivSight. In ActivPerfusion Mode, the device uses laser speckle technology on the entire view to show blood perfusion. Once enabled, the colorectal AI mode isolates the ActivPerfusion display to the targeted tissue, in this case, the colon, to minimize cognitive burden for the surgeon by eliminating the distraction of seeing blood perfusion in the entire scene. Activ Surgical said it is currently conducting a clinical study with Ohio State Wexner Medical Center to evaluate the utility and usability of ActivSight.
“At Activ Surgical, we are driven to learn from every procedure using enhanced, real-time visualization capabilities combined with augmented reality, artificial intelligence and machine learning technology so that we can deliver intelligent information to doctors around the world to reduce surgical complication rates,” said Manisha Shah-Bugaj, CEO at Activ Surgical. “With this latest milestone, we usher in a new standard of patient care and safety and will continue to build on our progress using AI technology.”
“With this procedure, we have shown that we can deploy proprietary models that have been trained with our datasets, annotated with our experts and our pipeline, and developed with our team and partners,” said Shah-Bugaj. “We are collaborating with global technology leaders to assist us with optimizing storage, integration, and inference. When all of this advanced tech is installed in the OR, our novel sensing brings it to life, and the results are incredible.”
In 2021, the ActivSight module was cleared by the FDA and successfully used in first-in-human/IRB studies. To date, multiple major hospital networks across the U.S. and Europe have been established as pilot sites, the company said. In 2022, ActivSight received CE Mark approval, which validates that it meets the requirements of the European Medical Devices Regulation, allowing Activ Surgical to commercialize the enhanced imaging system across the European Union and other CE Mark-required regions.
To learn more, visit the Activ Surgical website here.